Fractyl's Novel Diabetes Treatment Clears First Hurdle In Clinical Trial
Executive Summary
The first-in-human study of Fractyl's Revita duodenal mucosal resurfacing system shows significant short-term improvement in hyperglycemia in patients with type 2 diabetes, with few adverse events.
You may also be interested in...
Investors Boost Metabolic Companies
Investments in endocrine/metabolic disease-focused medtech companies reached a four-year high in 2015. Biopharma companies grabbed the majority of the funds that have been raised since 2012, and among medtechs, those focused on diabetes fared best.
News We’re Watching: SALSA Reintroduced, FDA Approves Abbott Valve, Metallic Implant Study
A bill aimed at preventing laboratory reimbursement cuts has been reintroduced in the US Congress. Additionally, an Abbott valve landed FDA approval, On Target Labs reported trial results, and the FDA warned that dental palate expanders may pose health risks to adults.
Minute Insight: Xeltis Expects The US Trial Of 'Living' Vascular Graft To Start This Year
Xeltis hemodialysis access graft, made of its proprietary electrospun supramolecular polymer material, is advancing in clinical trials in Europe and will likely be ready for a US trial by the end of this year, according to the company.